Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Saskia Eßer-Naumann"'
Autor:
Mathilde Louise Gehrchen, Tobias Berg, Rasmus Garly, Maj-Britt Jensen, Saskia Eßer-Naumann, Jeanette Dupont Rønlev, Hanne Melgaard Nielsen, Ann Knoop, Iben Kümler
Publikováno v:
BJC Reports, Vol 2, Iss 1, Pp 1-5 (2024)
Externí odkaz:
https://doaj.org/article/b7ed109fa6b54fd1a10b6903857bb409
Autor:
Mathilde Louise Gehrchen, Tobias Berg, Rasmus Garly, Maj-Britt Jensen, Saskia Eßer-Naumann, Jeanette Dupont Rønlev, Hanne Melgaard Nielsen, Ann Knoop, Iben Kümler
Publikováno v:
BJC Reports, Vol 2, Iss 1, Pp 1-8 (2024)
Abstract Background Initial treatment for advanced ER-positive/HER2-negative breast cancer involves a CDK 4/6 inhibitor (CDK 4/6i). Recent overall survival (OS) analyses led the Danish Medical Council to exclude palbociclib as preferred option. This
Externí odkaz:
https://doaj.org/article/d2612f5ad8f047cebfc8ffc4d7d6b96a
Autor:
Alan Celik, Tobias Berg, Magnus Gibson, Maj-Britt Jensen, Iben Kümler, Saskia Eßer-Naumann, Erik H. Jakobsen, Ann Knoop, Dorte Nielsen
Publikováno v:
Acta Oncologica, Vol 63, Iss 1 (2024)
Background and purpose: Capecitabine can be used as first-line treatment for advanced breast cancer. However, real-world data on efficacy of capecitabine in this setting is sparse. The purpose of the study is to evaluate outcomes of patients with Hum
Externí odkaz:
https://doaj.org/article/9a4a0d4feb1344fe96950898f4981baa